Published in Osteoporos Int on July 10, 2012
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab (2013) 1.60
Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int (2015) 1.53
Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov (2013) 1.53
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int (2015) 1.29
Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int (2015) 1.02
Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. J Bone Miner Res (2014) 1.01
A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Ther Adv Musculoskelet Dis (2011) 0.96
Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int (2015) 0.95
The contribution of cortical and trabecular tissues to bone strength: insights from denosumab studies. Clin Cases Miner Bone Metab (2013) 0.90
Chinese bone turnover marker study: reference ranges for C-terminal telopeptide of type I collagen and procollagen I N-terminal peptide by age and gender. PLoS One (2014) 0.88
A review of denosumab for the treatment of osteoporosis. Patient Prefer Adherence (2014) 0.86
Periprosthetic osteolysis after total hip replacement: molecular pathology and clinical management. Inflammopharmacology (2013) 0.83
Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis. Int J Clin Exp Pathol (2014) 0.81
Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis. Ther Adv Musculoskelet Dis (2015) 0.81
Observations following discontinuation of long-term denosumab therapy. Osteoporos Int (2017) 0.81
Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis. Drugs Aging (2014) 0.80
Chronic kidney disease and the skeleton. Bone Res (2014) 0.79
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis. Drug Healthc Patient Saf (2011) 0.79
Update on denosumab in postmenopausal osteoporosis--recent clinical data. Wien Med Wochenschr (2012) 0.76
New insights into treatment of osteoporosis in postmenopausal women. RMD Open (2015) 0.76
Denosumab: A bone antiresorptive drug. Med J Armed Forces India (2014) 0.76
Update on denosumab treatment in postmenopausal women with osteoporosis. Endocrinol Metab (Seoul) (2015) 0.75
Can lumbar spine bone mineral density predict readmission in denosumab-treated patients with chronic kidney disease? J Investig Med (2016) 0.75
Hypercalcemia after discontinuation of long-term denosumab treatment. Osteoporos Int (2016) 0.75
Osteoclast differentiation and activation. Nature (2003) 18.59
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A (1998) 12.61
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med (2004) 8.86
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res (2009) 2.99
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol (1999) 2.78
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res (2007) 2.68
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res (2009) 2.51
Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res (2010) 2.37
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res (2012) 2.34
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol (2000) 2.12
Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone (2008) 1.64
Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology (2000) 1.61
Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int (2004) 1.60
Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. Osteoporos Int (2010) 1.24
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab (2010) 1.12
Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone (2010) 1.07
Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res (2004) 1.03
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
A microagglutination technique for detection and measurement of rickettsial antibodies. Acta Virol (1969) 7.17
Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int (2014) 5.17
Selective trafficking of KNOTTED1 homeodomain protein and its mRNA through plasmodesmata. Science (1995) 4.40
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med (1990) 4.10
A classification of marginal tissue recession. Int J Periodontics Restorative Dent (1985) 3.62
A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int (2007) 3.50
Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet (2004) 3.45
Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med (1993) 3.23
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med (2000) 3.16
Calcium supplementation and increases in bone mineral density in children. N Engl J Med (1992) 3.13
Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 2.69
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
Relation between serum and urinary calcium with particular reference to parathyroid activity. Lancet (1969) 2.33
Limits of rickettsial infectivity. Infect Immun (1978) 2.31
The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int (2006) 2.24
Q fever endocarditis in the United States. Ann Intern Med (1979) 2.12
Surgical versus non-surgical endodontic re-treatment for periradicular lesions. Cochrane Database Syst Rev (2007) 2.09
Eosinophilic prostatitis and prostatic specific antigen. Br J Urol (1992) 2.04
Activity products in stone-forming and non-stone-forming urine. Clin Sci (1968) 1.87
Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporos Int (1993) 1.84
Immunoglobulin responses in acute Q fever. J Clin Microbiol (1985) 1.80
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
Serologic diagnosis of epidemic typhus fever. Am J Epidemiol (1977) 1.73
Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest (1997) 1.72
Effect of osteoarthritis in the lumbar spine and hip on bone mineral density and diagnosis of osteoporosis in elderly men and women. Osteoporos Int (1997) 1.71
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
The measurement and the meaning of urinary calcium. Clin Orthop Relat Res (1967) 1.65
Plasma 25-hydroxyvitamin D in pregnant Asian women and their babies. Lancet (1979) 1.63
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int (2002) 1.61
Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women. J Clin Invest (1996) 1.59
Management of prolonged pregnancy: induction of labor versus antepartum fetal testing. Am J Obstet Gynecol (1987) 1.56
Plaque assay of rickettsiae in a mammalian cell line. Appl Microbiol (1974) 1.56
Role of endothelial nitric oxide synthase in endothelial cell migration. Arterioscler Thromb Vasc Biol (1999) 1.56
Cytokine production and surface antigen expression by peripheral blood mononuclear cells in postmenopausal osteoporosis. J Bone Miner Res (1993) 1.55
Linkage of structure at the proximal femur to chromosomes 3, 7, 8, and 19. J Bone Miner Res (2003) 1.55
The cause of idiopathic calcium stone disease: hypercalciuria or hyperoxaluria? Nephron (1980) 1.55
Evaluation of the complement fixation and indirect immunofluorescence tests in the early diagnosis of primary Q fever. Eur J Clin Microbiol (1985) 1.55
Assay of plasma 25-hydroxy vitamin D. Clin Chim Acta (1976) 1.53
Parathyroid hormone: sequence, synthesis, immunoassay studies. Am J Med (1971) 1.53
Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab (2000) 1.51
Cardiac-specific overexpression of cyclin-dependent kinase 2 increases smaller mononuclear cardiomyocytes. Circ Res (2001) 1.50
Early effects of ethinyloestradiol and norethisterone treatment in post-menopausal women on bone resorption and calcium regulating hormones. Clin Sci (Lond) (1985) 1.47
Bone mineral density in relation to polymorphism at the vitamin D receptor gene locus. J Clin Invest (1994) 1.46
Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporos Int (2011) 1.45
Sibling pair linkage and association studies between bone mineral density and the insulin-like growth factor I gene locus. J Clin Endocrinol Metab (1999) 1.45
Cellular basis of potato spindle tuber viroid systemic movement. Virology (2001) 1.43
Genome screen for QTLs contributing to normal variation in bone mineral density and osteoporosis. J Clin Endocrinol Metab (2000) 1.43
Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis. Am Fam Physician (2000) 1.43
Coronal positioning of existing gingiva: short term results in the treatment of shallow marginal tissue recession. J Periodontol (1989) 1.42
Risk factors in calcium stone disease of the urinary tract. Br J Urol (1978) 1.41
Videoscopic lung volume reduction surgery in an Australian public teaching hospital. Aust N Z J Med (2000) 1.41
Geometric structure of the femoral neck measured using dual-energy x-ray absorptiometry. J Bone Miner Res (1994) 1.40
Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano) (2001) 1.40
Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab (2007) 1.39
"Evidence-based" or "logic-based" medicine? Osteoporos Int (2010) 1.38
Pharmacological differences between the human and rat vanilloid receptor 1 (VR1). Br J Pharmacol (2001) 1.35
Comparison of serum 25-OH vitamin D concentrations in rheumatoid arthritis and osteoarthrosis. Br Med J (1980) 1.32
Potato spindle tuber viroid as inducer of RNA silencing in infected tomato. Mol Plant Microbe Interact (2001) 1.32
Antigenic relationships between the typhus and spotted fever groups of rickettsiae. Am J Epidemiol (1978) 1.31
Racial differences in bone turnover and calcium metabolism in adolescent females. J Clin Endocrinol Metab (2003) 1.31
Reduced rates of skeletal remodeling are associated with increased bone mineral density during the development of peak skeletal mass. J Bone Miner Res (1997) 1.29
Root coverage using a free soft tissue autograft following citric acid application. Part 1: Technique. Int J Periodontics Restorative Dent (1982) 1.28
Spinal osteoporosis in men. Bone Miner (1989) 1.28
Quantitative ultrasound of the heel and fracture risk assessment: an updated meta-analysis. Osteoporos Int (2011) 1.28
Vitamin D receptor gene alleles and osteoporosis: a contrasting view. J Bone Miner Res (1995) 1.27
Do variations in hip geometry explain differences in hip fracture risk between Japanese and white Americans? J Bone Miner Res (1994) 1.26
Soy isoflavones do not affect bone resorption in postmenopausal women: a dose-response study using a novel approach with 41Ca. J Clin Endocrinol Metab (2006) 1.24
Posttraumatic stress two years after the Oklahoma City bombing in youths geographically distant from the explosion. Psychiatry (2000) 1.24
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. J Clin Endocrinol Metab (2009) 1.22
Urinary excretion of calcium and creatinine in relation to age and body weight in normal subjects and patients with renal calculus. Clin Sci (1970) 1.22
Calcium, magnesium, phosphorus, and parathyroid hormone interrelationships in pregnancy and newborn infants. Obstet Gynecol (1977) 1.22
Plasma 25-hydroxy vitamin D concentrations in patients with fractures of the femoral neck. Br Med J (1979) 1.22
Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab (2010) 1.21
ApaI, BsmI, EcoRV and TaqI polymorphisms at the human vitamin D receptor gene locus in Caucasians, blacks and Asians. Hum Mol Genet (1993) 1.20
Role of kidney in regulation of plasma-calcium. Lancet (1969) 1.20
Importance of dietary calcium in the definition of hypercalciuria. Br Med J (1967) 1.18
Possible involvement of the phloem lectin in long-distance viroid movement. Mol Plant Microbe Interact (2001) 1.18
Linkage of a QTL contributing to normal variation in bone mineral density to chromosome 11q12-13. J Bone Miner Res (1998) 1.18
Calcium retention in relation to calcium intake and postmenarcheal age in adolescent females. Am J Clin Nutr (1997) 1.17
Root coverage using the free soft tissue autograft following citric acid application. III. A successful and predictable procedure in areas of deep-wide recession. Int J Periodontics Restorative Dent (1985) 1.17
Genome screen for quantitative trait loci underlying normal variation in femoral structure. J Bone Miner Res (2001) 1.16
Development and validation of the mini-osteoporosis quality of life questionnaire (OQLQ) in osteoporotic women with back pain due to vertebral fractures. Osteoporosis Quality of Life Study Group. Osteoporos Int (1999) 1.15
Osteoporosis and osteomalacia. Clin Endocrinol Metab (1980) 1.15
Predictors of falls among postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int (2008) 1.15
Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women. Br Med J (Clin Res Ed) (1986) 1.14
Calcium absorption in the elderly. Calcif Tissue Res (1976) 1.14
Seasonal variations in urinary excretion of calcium. Br Med J (1974) 1.14
Non-autonomy of hormone secretion in primary hyperparathyroidism. Clin Endocrinol (Oxf) (1972) 1.13
Calcium oxalate crystalluria and urine saturation in recurrent renal stone-formers. Clin Sci (1971) 1.13
Saturation-inhibition index as a measure of the risk of calcium oxalate stone formation in the urinary tract. N Engl J Med (1976) 1.12
Comparison of BMD precision for Prodigy and Delphi spine and femur scans. Osteoporos Int (2006) 1.12
Oxidative stress and brain aging: is zinc the link? Biogerontology (2006) 1.12
Renal cell carcinoma: unusual systemic manifestations. Medicine (Baltimore) (1976) 1.11
Seasonal variations in the composition of urine in relation to calcium stone-formation. Clin Sci Mol Med (1975) 1.11